Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 23 of 23
Date Sort ascending
CL_2019-23.pdf

ACTION REQUIRED
Launch of Fibryga ® (Fibrinogen Concentrate - Human)

Customer Letter 2019-23 (PDF) | Product Profile Template FibrygaFibryga Customer Letter

CL_2019-22.pdf

INFORMATION ONLY
Correction: Summary of Results of 2019 Platelet Survey

Customer Letter 2019-22 (PDF)

CL_2019-21.pdf

INFORMATION ONLY
Launch of Panhematin (Hemin for Injection)

Customer Letter 2019-21 (PDF) | CBS Launch letter June 2019 | Panhematin Dosing Info Diff HCP Letter 2018 | Panhematin Product Profile | Sample Request for Patient Designated Plasma Protein Products

CL_2019-20.pdf

INFORMATION ONLY
Update to CUVITRU Supply

Customer Letter 2019-20 (PDF) | Customer Letter from Takeda

CL_2019-19.pdf

INFORMATION ONLY
Summary of Results of 2019 Platelet Survey

Customer Letter 2019-19 (PDF)

CL_2019-18.pdf

INFORMATION ONLY
Changes to Request Patient Designated Plasma Protein Products

Customer Letter 2019-18 (PDF) | Sample Request for Patient Designated Plasma Protein Products

CL 2019-17.pdf

INFORMATION ONLY
Launch of Hemlibra (emicizumub)

Customer Letter 2019-17 (PDF) | Hemlibra Product Profile | Sample Request for Patient Designated Plasma Protein Products | Dear Health Care Professionals letter

CL_2019-16.pdf

INFORMATION ONLY
Updates to Named Patient Program

Customer Letter 2019-16 (PDF) | Sample Request for Patient Designated Plasma Protein Products

CL_2019-15.pdf

INFORMATION ONLY
PANZYGA LOTS - Shelf Life Extension

Customer Letter 2019-15 (PDF) | PANZYGA LOTS– Shelf Life extension

CL_2019-14.pdf

INFORMATION ONLY
Gammagard Liquid Supply

Customer Letter 2019-14 (PDF) | Customer Letter from Takeda

CL_2019-13.pdf

INFORMATION ONLY
eProgesa Blood Component Label Change

Customer Letter 2019-13 (PDF)

CL_2019-12.pdf

INFORMATION ONLY
Eloctate®, Alprolix® and Alternate Plasma Protein Product Requests

Customer Letter 2019-12 (PDF) | Sample Request for Alternate Plasma Protein Products | Sample Request for Eloctate and Alprolix

CL_2019_11.pdf

INFORMATION ONLY
Use of fax emulating software solutions for Diagnostic Services Reports 

Customer Letter 2019-11 (PDF)

CL_2019-10.pdf

INFORMATION ONLY
Updates to Héma-Québec Component Codes and Héma-Québec Expiry Date of Irradiated Red Blood Cells

Customer Letter 2019-10 (PDF)

CL_2019-09.pdf

ACTION REQUIRED
Cuvitru Supply

Customer Letter 2019-09 (PDF) | TAKEDA Cuvitru Supply

CL_2019-08.pdf

ACTION REQUIRED
Change to RiaSTAP® Storage Conditions

Customer Letter 2019-08 (PDF) | Change to RiaSTAP® Storage Conditions

CL_2019-07.pdf

ACTION REQUIRED
Resume Routine Fresenius Kabi Pooled Platelet Bag Inspections

Customer Letter 2019-07 (PDF)

CL_2019-06.pdf

INFORMATION ONLY
Revision to Request: Patient Designated Plasma Protein Products Form

Customer Letter 2019-06 (PDF) | Request Patient Designated Plasma Protein Products

CL_2019-05.pdf

ACTION REQUIRED
Recombinant Factor VIII and IX Concentrates Contract Extensions and Product Availability (Further Information)

Customer Letter 2019-05 (PDF)

CL_2019-04.pdf

ACTION REQUIRED
Recombinant Factor VIII and IX Concentrates Contract Extensions and Product Availability

Customer Letter 2019-04 (PDF)

CL_2019-03.pdf

ACTION REQUIRED
Fresenius Kabi Platelet Bags

Customer Letter 2019-03 (PDF) | Fresenius Kabi - MEDICAL DEVICE RECALL

CL_2019-02.pdf

ACTION REQUIRED
Berinert® 1500IU Supply

Customer Letter 2019-02 (PDF) | CSL DCL Berinert 1500IU Supply

CL_2019-01.pdf

ACTION REQUIRED
Adynovate® approved by Health Canada for patients less than 12 years of age 

Customer Letter 2019-01 (PDF) | Adyovate Pediatric Indication Approval

Book now to donate blood